All HALT technology Articles
-
2.0KClinicalUnlocking the Potential of Combination Strategies: Why H.A.L.T. Spectacles and Low-Dose Atropine Have a Synergistic Effect
sponsored content June 16, 2025 By Dr. Bryan Sim, Consultant Ophthalmologist, Myopia Service, Singapore National Eye Centre (SNEC) Introduction: Addressing the Challenge...
-
2.9KClinicalNext-Gen Spectacle Designs for Myopia Management: What We Know Now
October 2, 2023 By Nabin Paudel, BOptom, PhD Myopia management using optical interventions, particularly spectacle lenses, has evolved over the past few...
-
1.7KLatest Myopia NewsTHE Myopia Meeting Lands in Vancouver for its Second Live Meeting of 2023
June 15, 2023 VANCOUVER, Canada — On Sunday, June 11, leaders in the eye care field gathered here for the second live...
-
1.9KLatest Myopia NewsTHE Myopia Meeting Brings Live Myopia Management Education to Canada
November 9, 2022 TORONTO – With Canada the first country to establish myopia management as the standard of care and offering more...
-
3.7KEditor’s PerspectiveInnovative Myopia Control Spectacle Lenses on the Horizon
June 1, 2022 By Dwight Akerman, OD, MBA, FAAO, FBCLA, FIACLE There is good reason to slow the progression of juvenile-onset myopia....
-
3.2KClinicalReview of Myopia Management Spectacles: MiYOSMART, Stellest, and SightGlass
June 1, 2022 By Dean Psarakis, B.Optom, Senior Research Optometrist, Brien Holden Vision Institute Novel spectacle designs comprising D.I.M.S., H.A.L.T., and D.O.T....
-
3.0KLatest Myopia NewsEssilor’s Two-Year Clinical Trial Data on Stellest Lenses Published in JAMA Ophthalmology
April 7, 2022 CHARENTON-LE-PONT, France — Essilor announced that its two-year clinical trial data on its Stellest lenses were published in JAMA...